Skip to content

Drug interactions

Efgartigimod / hyaluronidase sc + Ocrelizumab

Severity: Moderate

Efgartigimod / hyaluronidase sc and Ocrelizumab: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Efgartigimod blocks the neonatal Fc receptor and accelerates IgG catabolism. Ocrelizumab is an IgG1 antibody, so its exposure and effectiveness could be reduced.

What this interaction means in plain words

Efgartigimod / hyaluronidase sc and Ocrelizumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Evidence level: Low

Why it happens

Blockade of FcRn by efgartigimod reduces IgG recycling and lowers ocrelizumab concentrations.

What to do

Monitor for reduced ocrelizumab efficacy, such as B-cell repopulation or disease activity. Consider timing infusions away from efgartigimod cycles or choose an alternative.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Efgartigimod / hyaluronidase sc and Ocrelizumab, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Efgartigimod / hyaluronidase sc with Ocrelizumab?

MediHelp rates the interaction as moderate. Efgartigimod / hyaluronidase sc and Ocrelizumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Efgartigimod blocks the neonatal Fc receptor and accelerates IgG catabolism. Ocrelizumab is an IgG1 antibody, so its exposure and effectiveness could be reduced.

How serious is the interaction between Efgartigimod / hyaluronidase sc and Ocrelizumab?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for reduced ocrelizumab efficacy, such as B-cell repopulation or disease activity. Consider timing infusions away from efgartigimod cycles or choose an alternative.

What other medicines interact with Ocrelizumab?

MediHelp also lists interactions of Ocrelizumab with, for example, Adenovirus types 4 and 7 live, Influenza virus vaccine quadrivalent intranasal, Measles mumps and rubella vaccine live. The full list is on the Ocrelizumab page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in